NO20084688L - lmidazo[4,5-b]pyridin-2-on og oksazol[4,5-b]pyridin-2-onforbindelser og analoger derav cancerterapeutiske forbindelser - Google Patents
lmidazo[4,5-b]pyridin-2-on og oksazol[4,5-b]pyridin-2-onforbindelser og analoger derav cancerterapeutiske forbindelserInfo
- Publication number
- NO20084688L NO20084688L NO20084688A NO20084688A NO20084688L NO 20084688 L NO20084688 L NO 20084688L NO 20084688 A NO20084688 A NO 20084688A NO 20084688 A NO20084688 A NO 20084688A NO 20084688 L NO20084688 L NO 20084688L
- Authority
- NO
- Norway
- Prior art keywords
- independently
- linker
- compounds
- raf
- pyridin
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- JXXWJMUPNZDILL-UHFFFAOYSA-N imidazo[4,5-b]pyridin-2-one Chemical compound C1=CC=NC2=NC(=O)N=C21 JXXWJMUPNZDILL-UHFFFAOYSA-N 0.000 title abstract 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 title 1
- 239000012830 cancer therapeutic Substances 0.000 title 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 title 1
- 125000005647 linker group Chemical group 0.000 abstract 10
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 3
- 102000027426 receptor tyrosine kinases Human genes 0.000 abstract 3
- 108091008598 receptor tyrosine kinases Proteins 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 102000018471 Proto-Oncogene Proteins B-raf Human genes 0.000 abstract 2
- 108010091528 Proto-Oncogene Proteins B-raf Proteins 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000004663 cell proliferation Effects 0.000 abstract 2
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 125000005488 carboaryl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000002170 ethers Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- OVLXOTUWFLHWQT-UHFFFAOYSA-N oxazolo[4,5-b]pyridin-2(3H)-one Chemical class C1=CC=C2OC(=O)NC2=N1 OVLXOTUWFLHWQT-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Det beskrives visse imidazo[4,5-b]pyridin-2-on- og oksazolo[4,5-b]pyridin-2-on-forbindelser og analoger derav som blant annet inhiberer RAF (for eksempel B-RAF)-aktivitet, inhiberer celleproliferering, behandle cancer osv., og mer spesielt forbindelser med formlene, der: J uavhengig er -O- eller -NRN1; RN1, hvis tilstede, uavhengig er -H eller en substituent; RN2 uavhengig er -H eller en substituent; Y uavhengig er -CH= eller -N=; Q uavhengig er -(CH2)j-M-(CH2)k-, der: j uavhengig er 0, 1 eller 2; k uavhengig er 0,1 eller 2; j+k er 0, 1 eller 2; M uavhengig er O-, -S-, -NH-, -NMe- eller -CH2-; hver av RP1, RP2, RP5 og RP4 uavhengig er -H eller en substituent; og i tillegg RP1 og RP2 sammen kan være CH=CH-CH=CH-; og i tillegg RP1 og RP5 sammen kan være CH=CH-CH=CH-; L uavhengig er en linkergruppe dannet av en kjede på 2, 3 eller 4 linkerdeler; der hver linkerdel uavhengig er CH2-, -NRN-, -C(=X)- eller -S(=0)2; enten: nøyaktig en linkerdel er -NRN-, eller: nøyktig to linkerdeler er -NRN-; eller: nøyaktig en linkerdel er -C(=X)-; og ingen linkerdel er -S(=0)2-, eller: nøyaktig en linkerdel er -S(=0)2 og ingen linkerdel er -C(=X)-; ingen to nabo linkerdeler er -NRN-; X uavhengig er =0 eller =S; hver RN uavhengig er -H eller en substituent; A uavhengig er: C6-14 karboaryl, C5-14 heteroaryl, C3-12 karboksykel, C3-12 heterosykel; og er uavhengig usubstituert eller substituert; og farmasøytisk akseptable salter, solvater, amider, estere, etere, N-oksider, kjemisk beskyttede former og prodrugs derav. Det beskrives også farmasøytiske preparater omfattende slike forbindelser samt anvendelsen av slike forbindelser og preparater, både in vitro og in vivo, for å inhibere RAF (for eksempel B-RAF)-aktivitet, for å inhibere reseptor tyrosinkinase (RTK)-aktivitet, for å inhibere celleproliferering, og ved behandling og sykdommer og tilstander som lindres ved inhibering av RAF, RTK osv., proliferative tilstander som cancer (for eksempel kolorektal cancer, melanom), osv.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74563306P | 2006-04-26 | 2006-04-26 | |
| GBGB0608268.9A GB0608268D0 (en) | 2006-04-26 | 2006-04-26 | Therapeutic compounds |
| PCT/GB2007/001534 WO2007125330A1 (en) | 2006-04-26 | 2007-04-26 | Imidazo[4, 5-b]pyridin-2-one and oxazolo[4, 5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20084688L true NO20084688L (no) | 2009-01-26 |
Family
ID=38421488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20084688A NO20084688L (no) | 2006-04-26 | 2008-11-06 | lmidazo[4,5-b]pyridin-2-on og oksazol[4,5-b]pyridin-2-onforbindelser og analoger derav cancerterapeutiske forbindelser |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7951819B2 (no) |
| EP (1) | EP2013207B1 (no) |
| JP (1) | JP2009534457A (no) |
| AU (1) | AU2007245495A1 (no) |
| CA (1) | CA2649994A1 (no) |
| NO (1) | NO20084688L (no) |
| WO (1) | WO2007125330A1 (no) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009073513A1 (en) * | 2007-11-30 | 2009-06-11 | Schering Corporation | Braf biomarkers |
| WO2009077766A1 (en) | 2007-12-19 | 2009-06-25 | Cancer Research Technology Limited | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
| GB0807609D0 (en) * | 2008-04-25 | 2008-06-04 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| US9229008B2 (en) | 2008-08-19 | 2016-01-05 | Merck Sharp & Dohme Corp. | IL-8 level as a determinant of responsivity of a cancer to treatment |
| WO2011021678A1 (ja) * | 2009-08-21 | 2011-02-24 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| JP5760010B2 (ja) | 2010-02-01 | 2015-08-05 | キャンサー・リサーチ・テクノロジー・リミテッド | １−（５−ｔｅｒｔ−ブチル−２−フェニル−２Ｈ−ピラゾール−３−イル）−３−［２−フルオロ−４−（１−メチル−２−オキソ−２，３−ジヒドロ−１Ｈ−イミダゾ［４，５−Ｂ］ピリジン−７−イルオキシ）−フェニル］−尿素および関連化合物ならびに治療におけるそれらの使用 |
| US9131874B2 (en) | 2010-04-21 | 2015-09-15 | The Regents Of The University Of Michigan | Fluoroscopy-independent, endovascular aortic occlusion system |
| EP2710137B1 (en) | 2011-03-10 | 2018-09-19 | Provectus Pharmatech, Inc. | A combination of rose bengal and anti-ctla4 antibody for use in the treatment of cancer |
| WO2013022766A1 (en) * | 2011-08-05 | 2013-02-14 | Flynn Gary A | Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors |
| US9474882B2 (en) | 2013-02-26 | 2016-10-25 | Prytime Medical Devices, Inc. | Fluoroscopy-independent balloon guided occlusion catheter and methods |
| JP6343009B2 (ja) | 2013-09-09 | 2018-06-13 | プリタイム・メディカル・デバイシーズ・インコーポレイテッドＰｒｙｔｉｍｅ Ｍｅｄｉｃａｌ Ｄｅｖｉｃｅｓ，Ｉｎｃ． | 低輪郭閉塞カテーテル |
| GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| AU2015274743B2 (en) | 2014-06-10 | 2016-11-10 | Prytime Medical Devices, Inc. | Conduit guiding tip |
| CA2980018C (en) | 2015-03-19 | 2018-02-20 | Prytime Medical Devices, Inc. | System and method for low-profile occlusion balloon catheter |
| CA3012017A1 (en) | 2016-06-02 | 2017-12-07 | Prytime Medical Devices, Inc. | System and method for low-profile occlusion balloon catheter |
| CN109641892B (zh) * | 2016-08-16 | 2021-07-02 | 默克专利有限公司 | 用作可逆btk抑制剂的2-氧代-咪唑并吡啶及其用途 |
| EP4327732A3 (en) | 2017-01-12 | 2024-04-24 | The Regents of The University of California | Endovascular perfusion augmentation for critical care |
| JP2020518329A (ja) | 2017-04-21 | 2020-06-25 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 大動脈の部分遮断用の大動脈血流量計およびポンプ |
| CN114391009A (zh) | 2019-08-08 | 2022-04-22 | Bci制药公司 | 作为蛋白激酶抑制剂的喹啉衍生物 |
| TW202122082A (zh) | 2019-08-12 | 2021-06-16 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
| MX2022001863A (es) | 2019-08-12 | 2022-05-30 | Deciphera Pharmaceuticals Llc | Metodos para tratar los tumores del estroma gastrointestinal. |
| WO2021057696A1 (zh) * | 2019-09-27 | 2021-04-01 | 隆泰申医药科技(南京)有限公司 | 一种杂芳基类化合物及其应用 |
| AU2020417282B2 (en) | 2019-12-30 | 2023-08-31 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
| PL4084778T3 (pl) | 2019-12-30 | 2024-03-04 | Deciphera Pharmaceuticals, Llc | Formulacje amorficznych inhibitorów kinazy i sposoby ich zastosowania |
| US20210322026A1 (en) | 2020-03-16 | 2021-10-21 | Certus Critical Care, Inc. | Blood flow control devices, systems, and methods and error detection thereof |
| US11629143B2 (en) | 2020-10-01 | 2023-04-18 | Vibliome Therapeutics, Llc | HipK4 inhibitors and uses thereof |
| TWI812301B (zh) * | 2021-06-24 | 2023-08-11 | 南韓商Ｌｇ化學股份有限公司 | 作為ｒｏｎ抑制劑之新穎尿素衍生物化合物 |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5665863A (en) | 1979-10-31 | 1981-06-03 | Tokyo Organ Chem Ind Ltd | Novel aniline derivative, its preparation and pesticide containing the same |
| JPS5738777A (en) | 1980-08-19 | 1982-03-03 | Sogo Yatsukou Kk | 2-sufanilamidopyrathyn derivative |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5879672A (en) | 1994-10-07 | 1999-03-09 | Regeneron Pharmaceuticals, Inc. | Tie-2 ligand 1 |
| US5643755A (en) | 1994-10-07 | 1997-07-01 | Regeneron Pharmaceuticals Inc. | Nucleic acid encoding tie-2 ligand |
| AU701568B2 (en) | 1994-09-22 | 1999-02-04 | Licentia Ltd | Promoter for the receptor tyrosine kinase, tie |
| EP0951541B1 (en) | 1995-07-31 | 2005-11-30 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| ZA971896B (en) | 1996-03-26 | 1998-09-07 | Du Pont Merck Pharma | Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives |
| US6030831A (en) | 1997-09-19 | 2000-02-29 | Genetech, Inc. | Tie ligand homologues |
| NZ503432A (en) | 1997-09-26 | 2002-11-26 | Zentaris Gmbh | Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function |
| GB9721437D0 (en) | 1997-10-10 | 1997-12-10 | Glaxo Group Ltd | Heteroaromatic compounds and their use in medicine |
| GB2356398A (en) | 1999-11-18 | 2001-05-23 | Lilly Dev Ct S A | Preparation of arylsulfamides |
| JP2003518123A (ja) | 1999-12-21 | 2003-06-03 | スージェン・インコーポレーテッド | ４−置換７−アザ−インドリン−２−オンおよびその蛋白質キナーゼ阻害剤としての使用 |
| US6492529B1 (en) | 2000-01-18 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Bis pyrazole-1H-pyrazole intermediates and their synthesis |
| AU2002232439A1 (en) | 2000-11-29 | 2002-06-11 | Glaxo Group Limited | Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors |
| EP1456364B1 (en) | 2001-12-21 | 2011-03-23 | The Wellcome Trust | Mutations in the b-raf gene |
| JP4335136B2 (ja) | 2002-08-09 | 2009-09-30 | メルク エンド カムパニー インコーポレーテッド | チロシンキナーゼ阻害薬 |
| TW200616974A (en) | 2004-07-01 | 2006-06-01 | Astrazeneca Ab | Chemical compounds |
| CN101048388A (zh) | 2004-08-31 | 2007-10-03 | 阿斯利康(瑞典)有限公司 | 喹唑啉酮衍生物及其作为B－Raf抑制剂的用途 |
| GB0423554D0 (en) | 2004-10-22 | 2004-11-24 | Cancer Rec Tech Ltd | Therapeutic compounds |
-
2007
- 2007-04-26 US US12/298,325 patent/US7951819B2/en not_active Expired - Fee Related
- 2007-04-26 JP JP2009507165A patent/JP2009534457A/ja active Pending
- 2007-04-26 CA CA002649994A patent/CA2649994A1/en not_active Abandoned
- 2007-04-26 AU AU2007245495A patent/AU2007245495A1/en not_active Abandoned
- 2007-04-26 WO PCT/GB2007/001534 patent/WO2007125330A1/en active Application Filing
- 2007-04-26 EP EP07732571A patent/EP2013207B1/en active Active
-
2008
- 2008-11-06 NO NO20084688A patent/NO20084688L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2013207A1 (en) | 2009-01-14 |
| US20090325945A1 (en) | 2009-12-31 |
| JP2009534457A (ja) | 2009-09-24 |
| EP2013207B1 (en) | 2012-04-25 |
| AU2007245495A1 (en) | 2007-11-08 |
| US7951819B2 (en) | 2011-05-31 |
| WO2007125330A1 (en) | 2007-11-08 |
| CA2649994A1 (en) | 2007-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20084688L (no) | lmidazo[4,5-b]pyridin-2-on og oksazol[4,5-b]pyridin-2-onforbindelser og analoger derav cancerterapeutiske forbindelser | |
| NO20072546L (no) | Imidazo[4,5-b]pyridin-2-on og oksazolo[4,5-B]pyridin-2-on forbindelser og analoger derav som terapeutiske forbindelser | |
| CN109069504B (zh) | 氨基噻唑化合物及其用途 | |
| WO2006067466A3 (en) | Pyrazines and pyridines and derivatives thereof as therapeutic compounds | |
| JP2023065403A (ja) | 大環式化合物およびその使用 | |
| JP2020514409A (ja) | ジアリール大環状化合物を含む併用療法 | |
| NO20084927L (no) | Fosfoinositid-3-kinaseinhibitorforbindelser og farmasoytiske sammensetninger inneholdende dem | |
| KR20150023223A (ko) | Ｃｄｋ8/ｃｄｋ19 선택성 억제제 및 암에 대한 항-전이 및 화학예방 방법에서 이들의 용도 | |
| NO20074274L (no) | Tetrahydroindolon og tetrahydroindazolonderivater | |
| KR20110063573A (ko) | 시르투인 조절제로서의 크로메논 유사체 | |
| US11365189B2 (en) | Heterocyclic inhibitors of tyrosine kinase | |
| KR20110098789A (ko) | 시르투인 조절제로서의 이소인돌리논 및 관련 유사체 | |
| AU2013341271A1 (en) | Combination therapy | |
| NO20063768L (no) | 1H-tieno[2,3c] pyrazolderivater anvendelige som kinaseinhibitorer | |
| BRPI0614456B1 (pt) | 8-metoxi-9h-isotiazol[5,4-b]quinolina-3,4-dionas e compostos relacionados como agentes antiinfecciosos | |
| US10370400B2 (en) | 4-methylumbelliferone derivatives for treatment for immune modulation | |
| WO2016141159A1 (en) | Srebp blockers for use in treating liver fibrosis, elevated cholesterol and insulin resistance | |
| KR101532242B1 (ko) | 흑색종의 치료 | |
| JP2010535211A (ja) | 炎症性障害、脱髄障害および癌を治療するためのインダゾール化合物 | |
| EP2464642A1 (en) | Method of promoting apoptosis and inhibiting metastasis | |
| Hei et al. | Alkylsulfonamide-containing quinazoline derivatives as potent and orally bioavailable PI3Ks inhibitors | |
| CA2847091A1 (en) | Compositions and methods for treating cancer using pi3k.beta. inhibitor and mapk pathway inhibitor, including mek and raf inhibitors | |
| CN109071462A (zh) | 喹唑啉衍生物或其盐和包含其的药物组合物 | |
| CN117643587A (zh) | 用于治疗癌症的杂二环羧酸 | |
| EP3421039B1 (en) | Drug for cancer therapy characterized by administering combination between axl inhibitor and immune checkpoint inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |